

Cardiac Biomarkers: Market Research Report

<https://marketpublishers.com/r/C1D50838343EN.html>

Date: July 2018

Pages: 200

Price: US\$ 5,450.00 (Single User License)

ID: C1D50838343EN

Abstracts

This report analyzes the worldwide markets for Cardiac Biomarkers in US\$ Thousand by the following Testing Locations: Laboratory Testing, and Point of Care Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 39 companies including many key and niche players such as -

Abbott Diagnostics, Inc.

Quidel Corporation

Beckman Coulter, Inc.

BG Medicine, Inc.

biomérieux SA

Boditech Med Inc.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
Cardiac Biomarkers
Testing Location
Laboratory Testing
Point of Care Testing
Types of Cardiac Biomarkers
Cardiac Troponin
Natriuretic Peptides
BNP (B-type Natriuretic Peptide)
NT-proBNP (N-terminal proBNP)
Others
Creatine Kinase-MB (CK-MB)
Myoglobin

2. INDUSTRY OVERVIEW

A Curtain Raiser
Major Cardiac Markers and their Properties
Market Set to Record Strong Growth Led by Advancements in Cardiac Biomarker Combinations
North America Corners Biggest Slice, Asia-Pacific to Dictate Market Momentum
Laboratory Testing Remains Gold Standard, POC Testing Rapidly Gains Traction

Table 1. Rising Importance of Cardiac Biomarkers in the overall POCT Market (2017): Percentage Share of Cardiac Biomarkers, Cholesterol, Coagulation, Infectious Diseases, Pregnancy, Self-monitoring Blood Glucose and Others (includes corresponding Graph/Chart)

Analysis by Type of Cardiac Biomarker Assay/Test
Emerging Markets, New Product Introductions Hold Key to Reviving Saturated Cardiac Troponin Assays Market

Competitive Landscape

Intense Competition among Players in the Cardiac Diagnostics Market

Leading Vendors Focus on Curtailing Turnaround Time of POC Cardiac Testing Kits

Cardiac Markers Point-Of-Care Testing (POC) Cardiac Testing Segment: Major Players and their Operating Brands

Other Recent Innovations

Lipid Biomarker Panel to Detect HfrEF

VectraplexECG System with CEB Cardiac Electrical Biomarker

Cardiac Biomarkers on Smartphone

Stringent Regulations and Other Challenges

3. MARKET GROWTH DRIVERS, TRENDS & ISSUES

The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease

Table 2. Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart)

Population Explosion, Ballooning Geriatric Populace, Longer Life Expectancy Contributing to Rising Tide of CVDs

Table 3. Global Population Estimates (in Millions): 2017-2100 (includes corresponding Graph/Chart)

Table 4. Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)

Table 5. Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)

Table 6. Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)

Table 7. Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)

Cardiac Biomarkers Hold the Key to Timely, Accurate Diagnosis & Prognosis
Commercialization of Novel Biomarkers to Drive Market Growth
Personalized Medicine, Companion Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
Cardiac Biomarkers – A Powerful Tool for Patient Triaging
Cardiac Biomarkers Market Transitions from Mono-Marker to Multi-Marker Assays
Government Support Instrumental for Boosting Market Momentum
Secretoneurin Biomarker – a Potential Game Changer for Diagnosis of Cardiac Arrhythmias
High-Performance Techniques Drive Biomarker Discovery in Cardiology
Biomarkers for Acute Coronary Syndromes (ACS): A Leading Segment
Biomarkers – A Promising Diagnostic Tool for ACS
Biomarker Discovery for ACS to Undergo Significant Changes
Cardiac Biomarker Play Critical Role in Stroke Diagnosis
Cardiac Biomarkers to Find a Place in Neonatal Diagnosis and Treatment
Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market Growth

4. PRODUCT OVERVIEW

Cardiac Biomarkers
Necessity of a Cardiac Marker Assay Test
Cardiac Markers and Myocardial Infarction (MI)
Chain Reaction after an Event of MI
Action Plan after an Event of MI
Protocol for Conducting AMI Markers Tests
Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
Cardiac Markers and Congestive Heart Failure (Chf)
Types of Cardiac Biomarkers
Major Cardiac Markers and their Properties
Creatine Kinase – The Gold Standard Losing Sheen
Isomers
Kinetics
Purpose of Test and When to Order
Evaluation
Points to remember
Cardiac Troponin
Troponin Tissue-Specific Subtypes
Other Diseases
Uses of Troponin Tests

New Advanced High-sensitivity (Hs) Cardiac Troponin Tests

Myoglobin

Purpose of Test and When to Order

Testing and Evaluation

Points of Caution

Natriuretic Peptides

BNP (B-type Natriuretic Peptide)

NT-proBNP (N-terminal proBNP)

Purpose of Tests and When to Order

Testing and Evaluation

Points to Remember

Introduction of BNP Test and the Changing Market Scenario in the Segment: A Review

Choosing the Right BNP and NT proBNP Assay Kit in the Market

Evolution of BNP and NT proBNP Market

NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function

Other Important Cardiac Biomarkers

Homocysteine

C-Reactive Protein

Plasminogen Activator Inhibitor-1

D-Dimer

Thrombus Precursor Protein

Galectin-3 Biomarker

Galectin-3: An Overview of Clinical Studies

Galectin-3: Overview of Clinical Studies in Cardiovascular Disease Diagnosis

Potential Future Cardiac Biomarkers

Location of Cardiac Biomarker Testing

Laboratory Cardiac Testing

Point-of-Care Cardiac Testing

5. COMPETITIVE LANDSCAPE

5.1 Focus on Select Players

Abbott Diagnostics, Inc. (USA)

Quidel Corporation (USA)

Beckman Coulter, Inc. (USA)

BG Medicine, Inc. (USA)

biomérieux SA (France)

Boditech Med Inc. (South Korea)

Labsystems Diagnostics OY (Finland)

LifeSign LLC (USA)

LSI Medience Corporation (Japan)

Ortho-Clinical Diagnostics, Inc. (USA)

Randox Laboratories Ltd. (UK)

Response Biomedical Corp. (Canada)

Roche Diagnostics (Switzerland)

Siemens Healthineers (USA)

Merck KGaA (Germany)

5.2 Product Introductions

Prevenico Introduces Clinical Trial Business, and Targets to Release LDT Cardio Test by Year End

Prothena Presents Novel Research on Cardiac Biomarker NT-proBNP in AL

Amyloidosis at HFSA Annual Meeting

Fujirebio Europe Introduces the Lumipulse G hs Troponin I and Lumipulse G Myoglobin immunoassays

5.3 Recent Industry Activity

Beckman Coulter Diagnostics Receives Clearance from Health Canada for Access hsTnI

Ortho Clinical Diagnostics and Spingotec Announces Strategic Agreement Regarding Novel Biomarker

Abbott Acquires Alere Inc.

Bristol-Myers Squibb and Nordic Bioscience Collaborates for Fibrosis Biomarker Technology

6. GLOBAL MARKET PERSPECTIVE

Cardiac Biomarkers Testing By Geographic Region

Table 8. World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 9. World Historic Review Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$

Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 10. World 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 2024 Cardiac Biomarkers Testing By Location of Testing (includes corresponding Graph/Chart)

Table 11. World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 12. World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 13. World 14-Year Perspective for Cardiac Biomarkers in Laboratory Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

Table 14. World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 15. World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 16. World 14-Year Perspective for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US,

Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 20247 (includes corresponding Graph/Chart)

7. REGIONAL MARKET PERSPECTIVE

7.1 The United States

A. Market Analysis

Current and Future Analysis

Statistics for Cardiovascular Diseases and Stroke, and Related Risk Factors and Costs in the US

Table 17. Prevalence of heart disease (All types) in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above

Table 18. Prevalence of Coronary Heart Disease in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above

Table 19. Prevalence of Hypertension in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above

Table 20. Prevalence of Stroke in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above

Table 21. US Total Annual Average Expenditure for Cardiovascular Diseases by Type of CVD (2015): Percentage Breakdown of Expenditure for Heart Disease, Hypertension, Stroke and Other CVDs (includes corresponding Graph/Chart)

B. Market Analytics

Cardiac Biomarkers Testing By Location of Testing

Table 22. The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016

through 2024 (includes corresponding Graph/Chart)

Table 23. The US Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 24. The US 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.2 Canada Market Analysis

Table 25. Canadian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 26. Canadian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 27. Canadian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.3 Japan Market Analysis

Table 28. Japanese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 29. Japanese Historic Review Analysis for Cardiac Biomarkers by Location of

Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 30. Japanese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4 Europe

A. Market Analysis

Current and Future Analysis

Growing Prevalence of Cardiovascular Disease Propels Growth of European Cardiac Biomarkers Market

Cardiac Markers in Primary Care Sector

B. Market Analytics

Table 31. European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 32. European Historic Review Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 33. European 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

Cardiac Biomarkers Testing By Location of Testing

Table 34. European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 35. European Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 36. European 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.1 France Market Analysis

Table 37. French Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 38. French Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 39. French 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.2 Germany Market Analysis

Table 40. German Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 41. German Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015

(includes corresponding Graph/Chart)

Table 42. German 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.3 Italy Market Analysis

Table 43. Italian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 44. Italian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 45. Italian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.4 The United Kingdom A. Market Analysis Current and Future Analysis B. Market Analytics

Table 46. The UK Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 47. The UK Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 48. The UK 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.5 Spain Market Analysis

Table 49. Spanish Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 50. Spanish Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 51. Spanish 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.6 Russia Market Analysis

Table 52. Russian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 53. Russian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 54. Russian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.4.7 Rest of Europe Market Analysis

Table 55. Rest of Europe Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 56. Rest of Europe Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 57. Rest of Europe 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.5 Asia-Pacific Market Analysis

Table 58. Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 59. Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 60. Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

Cardiac Biomarkers Testing By Location of Testing

Table 61. Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 62. Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 63. Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.5.1 China Market Analysis

Table 64. Chinese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 65. Chinese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 66. Chinese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.5.2 India Market Analysis

Table 67. Indian Recent Past, Current and Future Analysis for Cardiac Biomarkers by

Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 68. Indian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 69. Indian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.5.3 Rest of Asia-Pacific Market Analysis

Table 70. Rest of Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 71. Rest of Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 72. Rest of Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.6 Latin America Market Analysis

Table 73. Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016

through 2024 (includes corresponding Graph/Chart)

Table 74. Latin American Historic Review Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 75. Latin American 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for Brazil, and Rest of Latin America Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

Cardiac Biomarkers Testing By Location of Testing

Table 76. Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 77. Latin American Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 78. Latin American 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.6.1 Brazil Market Analysis

Table 79. Brazilian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 80. Brazilian Historic Review Analysis for Cardiac Biomarkers by Location of

Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 81. Brazilian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.6.2 Rest of Latin-America
Market Analysis

Table 82. Rest of Latin-America Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 83. Rest of Latin-America Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 84. Rest of Latin-America 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

7.7 Rest of World
Market Analysis

Table 85. Rest of World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 86. Rest of World Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US\$ Thousand for Years 2011 through 2015

(includes corresponding Graph/Chart)

Table 87. Rest of World 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

8. COMPANY PROFILES

Total Companies Profiled: 39 (including Divisions/Subsidiaries - 44)

The United States (21)

Canada (1)

Japan (1)

Europe (15)

 France (1)

 Germany (2)

 The United Kingdom (2)

 Rest of Europe (10)

Asia-Pacific (Excluding Japan) (6)

I would like to order

Product name: Cardiac Biomarkers: Market Research Report

Product link: <https://marketpublishers.com/r/C1D50838343EN.html>

Price: US\$ 5,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1D50838343EN.html>